|1.||Kong, Xiang-Yi: 1 article (12/2014)|
|2.||Wang, Ren-Zhi: 1 article (12/2014)|
|3.||Gao, Jun: 1 article (12/2014)|
|4.||Li, Yong-Ning: 1 article (12/2014)|
|5.||Yang, Yi: 1 article (12/2014)|
|6.||Ma, Wen-Bin: 1 article (12/2014)|
|7.||Xing, Bing: 1 article (12/2014)|
|8.||Bydon, Ali: 1 article (11/2014)|
|9.||Macki, Mohamed: 1 article (11/2014)|
|10.||Gokaslan, Ziya L: 1 article (11/2014)|
05/01/1987 - "HLBI-MP regimen is thus expected to be useful in the clinical management of patients with multiple myeloma."
05/01/1987 - "Six patients with multiple myeloma were treated with HLBI-MP regimen; HLBI 300 X 10(4)U/day daily, Melphalan 4 mg/day p.o. "
02/01/2004 - "To investigate whether combination chemotherapy with vincristine, cyclophosphamide, prednisolone, and melphalan (COP/ MP) with the addition of ranimustine (MCNU) (MCNU-COP/MP) is superior to the slightly modified COP/MP (mCOP/MP) regimen in multiple myeloma (MM), a multicenter randomized study was performed. "
03/01/1991 - "The efficacy of alternating vincristine, melphalan (M), cyclophosphamide, prednisone/vincristine, carmustine, doxorubicin, and prednisone (VMCP/VBAP) polychemotherapy was compared with the M and prednisone (MP) regimen as induction treatment in multiple myeloma (MM). "
06/01/1993 - "To determine whether combination chemotherapy with alternating cycles of vincristine, cyclophosphamide, melphalan, and prednisone (VCMP) and vincristine, carmustine (BCNU), Adriamycin (doxorubicin; Farmitalia, Carlo-Erba Laboratories, Spain), and prednisone (VBAP) is better than the standard melphalan-prednisone (MP) regimen in multiple myeloma (MM). "
|2.||Spinal Cord Injuries (Spinal Cord Injury)
12/01/2014 - "Although the results of American National Acute Spinal Cord Injury Study 2 and 3 trials led to the wide adoption of a high-dose MP regimen for ASCI patients,the reliabilities of their study methods and data were still questionable. "
11/01/2014 - "Although the results of NASCIS (National Acute Spinal Cord Injury Study) II and III trials led to the widespread adoption of a high-dose MP regimen for patients treated within 8 hours of injury, subsequent studies have called into question the validity of NASCIS conclusions. "
11/01/1998 - "A randomized double-blind clinical trial was conducted to compare neurological and functional recovery and morbidity and mortality rates 1 year after acute spinal cord injury in patients who had received a standard 24-hour methylprednisolone regimen (24MP) with those in whom an identical MP regimen had been delivered for 48 hours (48MP) or those who had received a 48-hour tirilazad mesylate (48TM) regimen. "
|1.||Combination Drug Therapy (Combination Chemotherapy)